Case Report of Hemangiopericytoma Development After Prolonged Use of Oclacitinib Maleate in a Dog with Atopic Dermatitis and Iatrogenic Hyperadrenocorticism

Authors: Errante PR*

DOI: 10.23880/izab-16000605

Volume 7, Issue 4

Abstract

The canine atopic dermatitis is a chronic allergic disease that affects dogs genetically predisposed. Clinically, dogs present pruritus symptoms that lead to self-trauma. The most commonly used drugs are glucocorticoids to control pruritus, however, due to the genetic nature of the disease, there is a need for continuous and lifelong use of medication, which can lead to the development of iatrogenic hyperadrenocorticism. Therefore, others drugs such as cyclosporine, oclacitinib maleate and lokivetmab are recommended. The oclacitinib maleate is an inhibitor of the intracellular signaling pathway mediated by enzymes of the Janus kinase family, responsible by the activation of T lymphocytes and synthesis of cytokines with proinflammatory and pruritic activity and cytokines that participate in survival, development, growth and differentiation of T lymphocytes and cytokines that participate in survival, development, growth and Its use is restricted to dogs with atopic dermatitis that do not present an infectious or tumoral condition. This case report describes a 15-year-old female Lhasa Apso dog initially treated with glucocorticoids who developed iatrogenic hyperadrenocorticism. After replacement with oclacitinib maleate and its prolonged use, the dog presented the growth of three large nodules defined by histological analysis as hemangiopericytoma.

Keywords: Hemangiopericytoma; Cutaneous Tumor; Atopic Dermatitis; Oclacitinib Maleate; Adverse Effects

View PDF